WO1996040966A1 - Compositions et procedes de traitement de maladies associees a l'interleukine 6 (il-6) - Google Patents
Compositions et procedes de traitement de maladies associees a l'interleukine 6 (il-6) Download PDFInfo
- Publication number
- WO1996040966A1 WO1996040966A1 PCT/US1996/008679 US9608679W WO9640966A1 WO 1996040966 A1 WO1996040966 A1 WO 1996040966A1 US 9608679 W US9608679 W US 9608679W WO 9640966 A1 WO9640966 A1 WO 9640966A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- disorder
- cell
- cells
- culture medium
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 41
- 201000010099 disease Diseases 0.000 title claims abstract description 21
- 239000000203 mixture Substances 0.000 title claims description 27
- 238000000034 method Methods 0.000 title claims description 21
- 210000004027 cell Anatomy 0.000 claims abstract description 63
- 102000004889 Interleukin-6 Human genes 0.000 claims abstract description 38
- 108090001005 Interleukin-6 Proteins 0.000 claims abstract description 38
- 238000011282 treatment Methods 0.000 claims abstract description 35
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 29
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 claims abstract description 26
- 208000035475 disorder Diseases 0.000 claims abstract description 20
- 208000002193 Pain Diseases 0.000 claims abstract description 14
- 239000006143 cell culture medium Substances 0.000 claims abstract description 14
- 230000036407 pain Effects 0.000 claims abstract description 14
- 239000001963 growth medium Substances 0.000 claims abstract description 12
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 11
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 8
- 201000011510 cancer Diseases 0.000 claims abstract description 8
- 208000024891 symptom Diseases 0.000 claims abstract description 8
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 6
- 201000004681 Psoriasis Diseases 0.000 claims description 12
- 230000007423 decrease Effects 0.000 claims description 10
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 9
- 210000004185 liver Anatomy 0.000 claims description 9
- 206010028417 myasthenia gravis Diseases 0.000 claims description 8
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
- 238000004113 cell culture Methods 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 208000007465 Giant cell arteritis Diseases 0.000 claims description 4
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 4
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 4
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 4
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010037597 Pyelonephritis acute Diseases 0.000 claims description 4
- 201000001555 acute pyelonephritis Diseases 0.000 claims description 4
- 230000007170 pathology Effects 0.000 claims description 4
- 206010043207 temporal arteritis Diseases 0.000 claims description 4
- 208000006961 tropical spastic paraparesis Diseases 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010060937 Amniotic cavity infection Diseases 0.000 claims description 2
- 208000000103 Anorexia Nervosa Diseases 0.000 claims description 2
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 2
- 206010007134 Candida infections Diseases 0.000 claims description 2
- 206010061005 Cardiac myxoma Diseases 0.000 claims description 2
- 208000005024 Castleman disease Diseases 0.000 claims description 2
- 208000008158 Chorioamnionitis Diseases 0.000 claims description 2
- 208000000668 Chronic Pancreatitis Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 201000003874 Common Variable Immunodeficiency Diseases 0.000 claims description 2
- 206010053138 Congenital aplastic anaemia Diseases 0.000 claims description 2
- 208000028399 Critical Illness Diseases 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- 208000037162 Ductal Breast Carcinoma Diseases 0.000 claims description 2
- 201000009273 Endometriosis Diseases 0.000 claims description 2
- 201000004939 Fanconi anemia Diseases 0.000 claims description 2
- 206010018691 Granuloma Diseases 0.000 claims description 2
- 206010019375 Helicobacter infections Diseases 0.000 claims description 2
- 206010019659 Hepatic echinococciasis Diseases 0.000 claims description 2
- 241000484121 Human parvovirus Species 0.000 claims description 2
- 208000037147 Hypercalcaemia Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 206010020850 Hyperthyroidism Diseases 0.000 claims description 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 2
- 206010021263 IgA nephropathy Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 2
- 206010027202 Meningitis bacterial Diseases 0.000 claims description 2
- 206010027260 Meningitis viral Diseases 0.000 claims description 2
- 206010060880 Monoclonal gammopathy Diseases 0.000 claims description 2
- 208000019022 Mood disease Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 206010033647 Pancreatitis acute Diseases 0.000 claims description 2
- 206010033649 Pancreatitis chronic Diseases 0.000 claims description 2
- 206010061332 Paraganglion neoplasm Diseases 0.000 claims description 2
- 208000002774 Paraproteinemias Diseases 0.000 claims description 2
- 208000008071 Parvoviridae Infections Diseases 0.000 claims description 2
- 206010057343 Parvovirus infection Diseases 0.000 claims description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 201000000582 Retinoblastoma Diseases 0.000 claims description 2
- 206010040070 Septic Shock Diseases 0.000 claims description 2
- 208000005485 Thrombocytosis Diseases 0.000 claims description 2
- 208000033781 Thyroid carcinoma Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 206010044248 Toxic shock syndrome Diseases 0.000 claims description 2
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims description 2
- 208000037386 Typhoid Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 208000004064 acoustic neuroma Diseases 0.000 claims description 2
- 201000003229 acute pancreatitis Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 201000003894 alveolar echinococcosis Diseases 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 201000009904 bacterial meningitis Diseases 0.000 claims description 2
- 208000014581 breast ductal adenocarcinoma Diseases 0.000 claims description 2
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 claims description 2
- 208000003295 carpal tunnel syndrome Diseases 0.000 claims description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000010749 gastric carcinoma Diseases 0.000 claims description 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 2
- 230000000148 hypercalcaemia Effects 0.000 claims description 2
- 208000030915 hypercalcemia disease Diseases 0.000 claims description 2
- 208000003849 large cell carcinoma Diseases 0.000 claims description 2
- 208000006178 malignant mesothelioma Diseases 0.000 claims description 2
- 201000008265 mesangial proliferative glomerulonephritis Diseases 0.000 claims description 2
- 230000002956 necrotizing effect Effects 0.000 claims description 2
- 230000001599 osteoclastic effect Effects 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 208000007312 paraganglioma Diseases 0.000 claims description 2
- 201000011461 pre-eclampsia Diseases 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- 230000000241 respiratory effect Effects 0.000 claims description 2
- 201000006845 reticulosarcoma Diseases 0.000 claims description 2
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 201000000498 stomach carcinoma Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims description 2
- 208000005057 thyrotoxicosis Diseases 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 201000008297 typhoid fever Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 201000010044 viral meningitis Diseases 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 229940121354 immunomodulator Drugs 0.000 claims 2
- 238000004255 ion exchange chromatography Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 19
- 210000002966 serum Anatomy 0.000 abstract description 14
- 239000003112 inhibitor Substances 0.000 abstract description 6
- 238000002512 chemotherapy Methods 0.000 abstract description 5
- 230000003612 virological effect Effects 0.000 abstract description 3
- 239000011149 active material Substances 0.000 abstract description 2
- 229940100601 interleukin-6 Drugs 0.000 description 26
- 239000002609 medium Substances 0.000 description 25
- 102000004127 Cytokines Human genes 0.000 description 23
- 108090000695 Cytokines Proteins 0.000 description 23
- 230000003902 lesion Effects 0.000 description 14
- 239000006228 supernatant Substances 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 102000003390 tumor necrosis factor Human genes 0.000 description 10
- 108090001007 Interleukin-8 Proteins 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 210000003205 muscle Anatomy 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 5
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 5
- 102000003814 Interleukin-10 Human genes 0.000 description 5
- 108090000174 Interleukin-10 Proteins 0.000 description 5
- 239000012894 fetal calf serum Substances 0.000 description 5
- 239000000411 inducer Substances 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 206010061289 metastatic neoplasm Diseases 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 206010006002 Bone pain Diseases 0.000 description 4
- 108010009685 Cholinergic Receptors Proteins 0.000 description 4
- 208000003164 Diplopia Diseases 0.000 description 4
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 102000034337 acetylcholine receptors Human genes 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 206010015995 Eyelid ptosis Diseases 0.000 description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 3
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 102000004388 Interleukin-4 Human genes 0.000 description 3
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- RVOLLAQWKVFTGE-UHFFFAOYSA-N Pyridostigmine Chemical compound CN(C)C(=O)OC1=CC=C[N+](C)=C1 RVOLLAQWKVFTGE-UHFFFAOYSA-N 0.000 description 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 229960000890 hydrocortisone Drugs 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000017306 interleukin-6 production Effects 0.000 description 3
- 238000002595 magnetic resonance imaging Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229940090002 mestinon Drugs 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 201000003004 ptosis Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 102100032768 Complement receptor type 2 Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 206010019755 Hepatitis chronic active Diseases 0.000 description 2
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 208000010428 Muscle Weakness Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 102000004140 Oncostatin M Human genes 0.000 description 2
- 108090000630 Oncostatin M Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000014604 Specific Language disease Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000001078 anti-cholinergic effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 201000007201 aphasia Diseases 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000010908 decantation Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 210000004976 peripheral blood cell Anatomy 0.000 description 2
- -1 polypropylene Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001185 psoriatic effect Effects 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 238000011301 standard therapy Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 208000037415 AIDS wasting syndrome Diseases 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 206010061728 Bone lesion Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 208000003577 HIV wasting syndrome Diseases 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000840267 Homo sapiens Immunoglobulin lambda-like polypeptide 1 Proteins 0.000 description 1
- 101000759926 Homo sapiens Ubiquitin carboxyl-terminal hydrolase isozyme L1 Proteins 0.000 description 1
- 102100029616 Immunoglobulin lambda-like polypeptide 1 Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 102100025038 Ubiquitin carboxyl-terminal hydrolase isozyme L1 Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000001004 anti-acetylcholinic effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000019189 interleukin-1 beta production Effects 0.000 description 1
- 230000031261 interleukin-10 production Effects 0.000 description 1
- 229940076264 interleukin-3 Drugs 0.000 description 1
- 230000021995 interleukin-8 production Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000003076 neurotropic agent Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000014237 psoriasis 1 Diseases 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/91—Cell lines ; Processes using cell lines
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to methods and compositions for treatment of a variety of disorders characterized by elevated IL-6 levels, and is based on materials derived from a transformed B cell line.
- cytokines have now been purified, cloned and expressed in recombinant hosts. Clinical trials have shown some success, however, there is toxicity in many cases at effective doses and more recent efforts have focused on searches for inhibitors of cytokines. It is therefore an object of the present invention to provide compositions and methods for treatment of disorders associated with elevated levels of cytokines. It is a further object of the present invention to provide compositions for treatment of disorders associated with elevated levels of
- Transformed B cell lines secrete into a human serum culture medium under controlled conditions an inhibitor of IL-6.
- the cell culture medium, or purified fractions thereof having IL-6 inhibitory activity can be administered to treat patients having disorders characterized by elevated levels of IL-6, particularly certain types of cancers, autoimmune disorders, pain associated with these disorders, side effects arising from chemotherapy, and wasting or other symptoms of certain viral diseases.
- the preferred cell line is RPMI 1788, from the American Type Culture Collection, although other B cell lines can also be used as a source of active material.
- compositions include compositions containing cell secretions produced by B lymphoid cells, induced with a transforming agent such as infection with Epstein Barr vims, and cultured in a human albumin or semm based culture medium or synthetic medium, as obtained by centrifugation or filtration of the cell culture media or in purified form.
- a transforming agent such as infection with Epstein Barr vims
- Cells that can be cultured to produce the pharmaceutical compositions are primarily hematopoietic cells, especially human B lymphoid cell lines transformed by Epstein Barr Vims.
- the most preferred cell line is RPMI 1788, deposited with the American Type Cell Culture Collection under Accession Number CCL 156, which has been previously exposed to Epstein-Barr vims.
- This cell line is Epstein-Barr vims nucleic antigen-positive, as is about 60% of the human population.
- the cell culture medium containing the secretions from these cells is referred to herein as "LK-200", although secretions from only one cell line, ATCC CCL 156, is currently being tested clinically.
- EBV transformed cell lines such as IB4, Raji, which is a Burkett lymphoma cell line, and non- EBV infected B cell lines such as Bjab. These cell lines can be obtained from the ATCC or other sources, for example, Tufts New England Medical Center, Boston, Massachusetts.
- Inducing Agents Agents which can be used to transform the cells include viruses such as Epstein Barr vims. Inducers, which may be used alone in some cases or in combination with transforming agents, include tumor necrosis factor (TNF), endotoxin, and other agents known to those skilled in the art.
- TNF tumor necrosis factor
- the cultured cells are exposed to an amount effective to activate the cells, as determined by cytokine expression, immunoglobulin secretion, and/or other indicators such as proliferation or alteration of cell surface properties or markers.
- cells are initially exposed to a small amount to "prime” the cells, then to a subsequent dose to elicit greater activation of the cells.
- the inducing agent is removed from the cell culture medium when the medium is exchanged, either through gradual supplementation or filtration or centrifugation of the cells, followed by decantation of the medium and replacement with fresh medium.
- the cells are preferably cultured in a medium which can be administered directly to a human patient without eliciting a reaction to the medium.
- the medium is based on 2% AB human semm, for example, obtained from Bio Whittaker, Inc., Walkersville, MD,or Gibco, Life Technologies, Inc., Grand Island, NY, although albumin can be substituted for the semm immediately prior to harvesting of the cell culture medium.
- Human serum is placed in Iscove's Modified Dulbecco's Medium (IMDM) containing sodium bicarbonate and 25 mM HEPES in a concentration of 2% L-glutamine.
- IMDM and L-glutamine can also be obtained from Bio Whittaker.
- Semm source does have an effect on cytokine levels in the final product, although it is relatively negligible.
- the level of IL- 8 in Bio Whittaker semm medium after removal of the cells (referred to as "supernatant", regardless of the method of cell removal) was measured as 0.367 ⁇ 0.17 ng IL-8/ml and the level of IL-8 in Gibco serum medium was measured as 0.184 _+ 0.1 ng IL-8/ml; the level of TNF in the Bio Whittaker serum medium was 0.311 ⁇ 0.24 ng TNF/ml and the level of TNF in the Gibco semm medium was 0.179 +. 0.07 ng TNF/ml. Cells will grow and secrete active components in albumin, but only to a limited extent.
- the blood type of the semm source can elicit a reaction in some patients having a different blood type. Accordingly, although not a problem, it is preferred to utilize a serum source of the same blood type as the patient.
- Cells are incubated at 37 °C until they reach a minimum density of 1 x 10 6 cells/ml.
- the pH at the time of harvest is approximately 7.00 _+ 0.15.
- RPMI 1788 cells obtained from the ATCC are thawed in a 37 °C water bath, suspended at room temperature in 0.2 micron-filtered Iscov's media containing HEPES, obtained from GIBCO BRL Life Technologies, Inc., Gaithersburg, MD, and supplemented with 2% glutamine and 2 to 5% normal human semm (Gibco) or 10 to 25% human albumin (Gibco).
- Cells are cultured in T75 flasks in an atmosphere of 5% CO 2 at 37 °C until the cell density exceeds 1 x 10 6 cells/ml.
- the cells can then be removed by centrifugation at 800 x g for 5 minutes or filtration and resuspended in T 150 flasks at a density of 0.2 x 10 6 cells/ml in a total volume of 200 mis of media. Cells are then cultured again until the density reaches 1 x 10 6 cells/rnl and the process is repeated. Cells can then be cultured in 500 ml roller bottles, flushed with 10% CO 2 and sealed, at an initial cell density of 0.2 x 10 6 cells/ml, until the cells reach a density of at least 1 x 10 6 cells/ml.
- LK200 LK200
- IB4 peripheral blood cells
- PBCs peripheral blood cells activated by exposure to a mitogen, PHA, and controls: 2% human semm medium not exposed to cells, 10% fetal calf serum (FCS) medium not exposed to cells, and a T cell line OKT3.
- FCS fetal calf serum
- Table 1 demonstrates that the RPMI 1788 cells only weekly express the lambda light chain.
- RPMI 1788 cells labelled "ATCC" (presumably not propagated in vitro since the initial purchase of the line) are markedly positive for this antigen.
- the RPMI 1788 line does not express the "naive" CD45 isoform found on the other lines.
- This line is, however, reactive with the Becton Dickinson HLe-1 mAb.
- the line may express an isoform containing material encoded by the B alone or the B and C exons. Regardless of the structure of this isoform, the sigmficance of this variant is obscure.
- (+) and (-) signs indicate 100% and 0% expression respectively.
- the RPMI 1788 and IB4 cell lines are EBV+LCL.
- Raji is a Burkitt lymphoma and Bjab a non-EBV-infected B cell line.
- All mAb used in these FACS analyses were FITC-conjugated except the anti-CD21.
- the unconjugated anti-CD21 mAb was used with an anti-murine IgG-FITC second step antibody to detect CD21 surface expression.
- IL-1 beta, TNF, IL-6, IL-10, IL-IRA, soluble IL-1 receptor type II (sIL-IRII), and IL-8 were assayed by RIA.
- IL-2, IL-4, GM-CSF, and IFN-gamma were assayed by ELISA with kits obtained from Endogen.
- IL-12 was similarly assayed with a kit from R&D Systems.
- LK200 and RPMI 1788 supematants contain modest amounts of IL-8 (consistently less than 135 pg/ml) and modest amounts of TNF (less than 250 pg/ml).
- Supernatant from the Bjab line contains a great deal of IL-10 (920 pg/ml). This is the one B cell line studied that is not EBV-infected.
- the IB4 line sheds the type II IL-1 receptor (1,100 pg/ml).
- the Bjab line secretes a modest amount (227 pg/ml) of the IL-IRA.
- the donor of the PBMC for this experiment was Damien Sorce.
- 12.5 x 10 6 cells were incubated in 5 ml total volume in 50 ml polypropylene centrifuge tubes which had been previously coated with human albumin (10 ⁇ g/ml x 1 hr).
- Cells were cultured in RPMI medium supplemented with 2% human AB serum and 4 ⁇ g/ml polymyxin B.
- the PBMC were vortexed briefly to ensure equilibration of the secreted cytokines throughout the culture medium and then pelleted by centrifugation. The supematants were removed and frozen under sterile conditions for future analysis.
- IL-IRA soluble IL-1 receptor type II
- IL-8 soluble IL-1 receptor type II
- IL-2, IL-4, GM-CSF, and IFN-gamma were assayed by ELISA with kits obtained from Endogen.
- IL-12 was similarly assayed with a kit from R&D Systems.
- LK200 The 2% human AB semm used in the generation of LK200 itself induces an abundance of IL-6, IL-8, and IL-IRA, presumably due to FcR signalling.
- composition not only serves as an inhibitor but is more effective when diluted to lower concentrations, presumably as a result of inhibition or competitive mteractions with other components of the composition.
- the pharmaceutical composition can consist of the culture medium alone or diluted with deionized water or normal saline (0.15 N NaCl) or other physiological buffer. Care should be taken to avoid changes in pH. The medium should not be diluted until immediately prior to administration to the patient.
- the cells are removed from the culture medium to yield a supernatant containing the biologically effective molecules.
- Cells can be removed by centrifugation or filtration.
- the medium is withdrawn from the roller bottles by decantation, pipetting, filtration or centrifugation, then the medium is placed into sterile syringes. Further processing of the material can be obtained based on separation by molecular weight, chromatography on ion-exchange resins, and other methods known to those skilled in the art, where the active fraction is defined by inhibition of IL-6 activity. Sterilization Sterility can be assured by culturing the cells under standard sterile conditions, with removal of the cell culture medium using aseptic conditions.
- the cell culture medium can be purified by filtering with a filter not excluding molecules of less than 250,000, or more preferably, not less 150,000 daltons, for example, a 0.25 micron filter.
- the culture medium may also be sterilizable using gamma irradiation.
- the supernatant once removed from 37°C temperature and 10% nitrogen atmosphere of the cell culture bottles and separated from the cells, can be maintained at room temperature for at least two to four hours without any loss of activity.
- the medium should be rapidly frozen (defined as in less than two hours) in liquid nitrogen, on dry ice, or in an ultrafreezer, at a temperature of about -40°C to -80°C.
- Assays on 45 lots of LK-200 for various cytokines indicate that concentrations are in the nanogram per milliliter range, as shown in Table 2. All lots showed essentially no batch to batch variation. There is some direct correlation with levels of cytokines with human serum concentration in the media.
- the endotoxin levels in the supematants have consistently measured at or less than 10 pg endotoxin/ml. In general, levels up to 10 ng are acceptable for administration to a patient.
- Interleukin-6 is a pluripotent cytokine that has an effect on a wide array of different cell types. It is generally recognized as a B-cell growth factor, originally being identified as an inducer of immunoglobulin secretion in the Esptein-Barr Vims (EBV) transformed CESS lymphoblastoid line. Although it is classified as an acute phase protein, its role is multifaceted and remains somewhat cloudy. Clearly, it is an important cytokine thought to be intimately involved in several pathologies.
- the receptor for IL-6 is gpl3O. This is a transmembrane, transducing receptor which spans the cell membrane and signals the cell once the ligand is bound. Sharing the gpl3O receptor with IL-6 are other cytokines including Leucocyte Inhibitory Factor (LIF), Oncostatin M (OSM), IL-11 and Ciliary Neurotropic Factor (CNTF).
- LIF Leucocyte Inhibitory Factor
- OSM Oncostatin M
- CNTF Ciliary Neurotropic Factor
- Inhibitors of IL-6 are retinoic acid and some steroids (dexamethasone). Soluble gpl3O at one time had been considered to be inhibitory for IL-6 activity. Binding of IL-6 with soluble gp!3O, however, exacerbates its pathological effects, particularly osteoclast formation. In some diseases, multiple myeloma and Kaposi's sarcoma for example, IL-6 is thought to play an autocrine or paracrine role. In these cases, IL-6 is both generated and then used by the same or adjacent cells, perpetuating the disease.
- IL-6 has been implicated include the following: Multiple myeloma (mm); Prostate cancer; Ovarian cancer;
- Critical illness polyneuromyopathy Acute pyelonephritis; Autoimmune hepatitis; Large-cell lymphoma; Alveolar echinococcosis; Endometriosis; Atherosclerosis; Psoriasis; Human Parvovirus infection; Renal cell carcinoma; Preeclampsia; Cholangiocarcinoma; HIV; Acoustic neuromas;
- Hairy-cell leukemia Necrotizing enterococlitis; Ulcerative colitis;
- Retinoblastoma Pituitary tumors; Acute pyelonephritis; Thyroid carcinoma; Paraganglioma; Candida albicans infection; Giant cell arteritis;
- Psoriasis Melanoma; Chronic pancreatitis; Carpal tunnel syndrome;
- Uterine cancer Pulmonary Large cell carcinoma; Helicobacter pylori infections; Ductal Breast carcinoma; Granulomas of giant cell arteritis;
- Thyrotoxicosis Osteosarcoma
- Malignant mesothelioma Malignant mesothelioma
- Typhoid fever Typhoid fever
- IgA nephropathy Acute pancreatitis; Fanconi's anemia; Paraneoplastic thrombocytosis; and Cystic fibrosis.
- Dosages and administration schedules are highly individual and are optimized individually in response to alleviation of clinical symptoms, for example, reduction in tumor mass, relief from bone pain, and other subjective or objective criteria. Cancers and Viral Diseases
- tumor size can be monitored by standard tumor detection and measurement methods such as CAT scanning (computerized axial tomography), MRI (magnetic resonance imaging), and nuclear medicine scans, as known to those of skill in the art.
- Progression and involvement of lesions caused by a vims or total anatomic involvement of the disease which are herein used as indicators of the progression of the disease, can be determined by standard methods known in the art for each specific lesion type, depending upon the specific disease, for example, organ function or antibody titers.
- effectiveness can be measured as a reduction in the intensity and duration of the symptoms of the invention. This can include measurement of pathologic and pathophysiologic activities that are reduced, for example, elevated liver functions, elevated bilirubin levels, enlarged liver size and enlarged spleen.
- the composition is also effective in reducing side effects of chemotherapy and radiation therapy.
- Side effects which can be reduced include nausea, vomiting and hair loss. Pain is also reduced in many cases. Pain remission can include remission of pain from a decrease in tumor size or in space-occupying lesions, thus decreasing organ pressure and compression of anatomical structures (i.e., nerves, vessels and other organs), as well as remission in pain not associated with a decrease in tumor size or a decrease in lesions, such as pain in bones and other pain remission that occurs before a significant decrease in tumor size or lesions occurs.
- anatomical structures i.e., nerves, vessels and other organs
- Autoimmune Disorders Treatment of Autoimmune Disorders
- Autoimmunity is described as an immune response mounted against self-components which ultimately results in pathogenic consequences. Diseases which result from autoimmune responses are widespread and varied in clinical presentation.
- One common factor shared by many of these disease entities is the lack of a known etiologic agent or triggering event for the production of these aberrant responses.
- Rheumatological illnesses encompass a large number and wide spectmm of different autoimmune diseases, such as rheumatoid arthritis, scleroderma, dermatomyositis, polymyositis, discoid lupus erythematosus, Sjogren's syndrome and systemic lupus erythematosus.
- Myasthenia Gravis is a disease of unknown etiology, characterized by circulating antibodies to acetylcholine receptors.
- the disease is manifested by muscle weakness with a predilection for ocular and other cranial muscles. It has a tendency to fluctuate in severity. There are no signs of neurological lesions.
- the disease is believed to have an immunological basis and anticholinergic antibodies binding to acetylcholine receptors are found in most patients with the disease. Patients may also present with anti-muscle antibodies.
- the anticholinergic antibodies effectively reduce the number of functional acetylcholine receptors. It is also believed that cellular immune activity against receptors has been found. Patients exhibit generalized weakness that may be fluctuating, most commonly in the use of voluntary muscles.
- Symptoms such as diplopia, ptosis, and dysphasia are noted. Activity increases weakness of affected muscles. In some cases, efficacy will be demonstrated by reduction in autoantibody levels, in other cases by a decrease in the severity of symptoms. For example, efficacy can be demonstrated by an improvement in large muscle and proximal muscle dysfunction, a reduction in anti-acetylcholine activity, reduction in anti- smooth muscle antibody levels, and improvement in swallowing dysfunctions and dysphasia. Dosages The general method of administration and dose schedule for LK-
- LK-200 is as follows. Frozen LK-200 is thawed in less than two hours, without excessive heating or mechanical agitation. 50 cc of the LK-200 is then mixed with 50 to 100 cc of normal saline. In some instances, depending upon disease or response, 100 to 200 cc of LK-200 may be mixed with 50 to 100 cc of sterile normal saline. In general, 50 cc mixed with 50 to 100 cc of Sterile Normal Saline is administered once daily for the first 10 to 14 days and then on a three times a week schedule. In some circumstances, up to 200 cc of LK-200 mixed with 50 to 100 cc sterile normal saline is administered four times a day. The mixture is infused intravenously over a 5 to 45 minute period, depending upon " the total volume to be administered. A slower rate is sometimes used if there is a possibility of cardiac decompensation in a patient.
- the intravenous administration can be accomplished peripherally through normal intravenous injection.
- patients have specialized ports, such as a Hieman Catheter, which can be used for infusion. This includes certain sub-clavian catheters which are used for chemotherapy and or hyperalimentation or other accepted uses of these catheters.
- the LK-200 can also be administered via a direct intra-arterial infusion on a selective basis, or via intra-peritoneal infusion.
- Portable infusion pumps may be preferred in some cases.
- Dosages can be varied from one to four doses daily or decreased to one every other day or two or three times a week. Dosages typically will be equivalent to between 0.1 and 100 cc/day, averaging about 10 to 50 cc administered once or twice a day or every other day.
- dosages as provided above are based on administration of the cell culture medium. In the event that the purified fractions are used, the dosage will be adjusted accordingly.
- Example 1 Treatment of Cancer Patients.
- Day 1 through Day 7 One daily dose of 10 - 50 ml LK 200 was administered intravenously in 100 ml normal saline, over 15 to 30 minutes.
- LK 200 Upon administration of the first dose of LK 200, patients experienced the following immediate effects, i.e., within about 24 - 48 hours, in addition to the immediate tumor shrinkage detailed in Table 4: remission of pain; increase in appetite; increase in energy, halting of wasting; increase in quality of sleep.
- Table 4 provides data from patients treated with LK 200, detailing the regression of specific tumors or lesions associated with the listed disease. Tumors and lesions were measured by CAT scan, MRI and visual inspection.
- Prior record immunocompromised male due to HIV; CD4 counts less than 25; prior treatment included interferon 3 times per week for 1 year, with no regression of the multiple lesions.
- Example 2 Treatment of patients with psoriasis. Psoriatic keratinocytes (skin cells) produce and respond to IL-6.
- a second patient with psoriasis associated with malignant myeloma was treated with LK-200.
- the psoriasis had been unresponsive to traditional medical treatment.
- Example 3 Treatment of patient with Rheumatoid Arthritis.
- LK-200 suppresses the generation of inflammatory cytokines.
- the sedimentation rate in other patients being treated with LK-200 have also fallen dramatically regardless of the type of tumor or underlying immunologic disease.
- the sed rate (ESR) is a cmde index of the severity of an ongoing inflammatory disorder. It is largely determined by the plasma level of fibrinogen, a coagulation protein produced in the liver.
- the production of fibrinogen is regulated by IL-6.
- a precipitous decline in the ESR could therefore be due to the suppression of IL-6 production or to interference with its biologic effects.
- Rheumatoid Arthritis who was refractory to all forms of conventional therapy including gold treatments and methotrexate therapy was treated with LK-200.
- the patient had a sed rate of 60 at the start of therapy.
- LK-200 was administered for two weeks. After two weeks of therapy, the patient's sed rate had returned almost to normal at around 15-20. She had no further pain in her hands and she was able to resume household chores.
- Example 4 Treatment of female patient with myasthenia gravis.
- the patient is a thirteen year old white female with an established diagnosis of Myasthenia Gravis. She was in an extremely weakened condition, in a wheel chair, unable to lift her head, and unable to easily move any of her large peripheral muscle groups. She had a strongly positive Hess test for ocular paralysis. She had extreme ptosis, with moderate diplopia. The patient had a peak flow of 325 cc prior to the start of therapy. She was maintained on Mestinon 60 milligrams every two hours during the day and 180 milligrams at bedtime.
- Method Sterile thawed LK-200 was administered i.v. to the patient over a period of 20 to 45 minutes. 50 cc of LK-200 was mixed with in 50 cc of sterile normal saline and prepared for infusion by peripheral intravenous injection. The IV solution was administered to the patient daily on Monday through Friday for two weeks.
- acetylcholine antibodies and anti-smooth muscle antibodies further demonstrate efficacy. After ten days of treatment with LK-200, the level of acetylcholine receptor antibodies was 3.9 nmols/L. After an additional month of treatment the level had decreased to 3.0 nmols/L.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Des lignées de lymphocytes B transformées sécrètent dans un milieu de culture à base de sérum humain, et dans des conditions régulées, un inhibiteur d'IL-6. Il est possible d'administrer ce milieu de culture cellulaire ou des fractions purifiées de celui-ci, présentant une action inhibitrice par rapport à IL-6, à des patients afin de traiter des affections caractérisées par des niveaux élevés d'IL-6, notamment certains types de cancer, des affections auto-immunes, des douleurs associées à ces troubles, des effets secondaires découlant d'une chimiothérapie, le dépérissement ou d'autres symptômes de certaines maladies d'origine virale. La lignée cellulaire préférée est la lignée RPMI 188, de l'American Type Cell Culture Collection, encore que l'on puisse également faire appel à d'autres lignées de lymphocytes B comme source de substance active. Des exemples démontrent l'efficacité de telles lignées dans le traitement de patients atteints de cancer ainsi que dans le traitement d'affections auto-immunes.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU60381/96A AU6038196A (en) | 1995-06-07 | 1996-06-04 | Compositions and methods of treating il-6 associated disease s |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48712295A | 1995-06-07 | 1995-06-07 | |
US487,122 | 1995-06-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996040966A1 true WO1996040966A1 (fr) | 1996-12-19 |
Family
ID=23934508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/008679 WO1996040966A1 (fr) | 1995-06-07 | 1996-06-04 | Compositions et procedes de traitement de maladies associees a l'interleukine 6 (il-6) |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU6038196A (fr) |
WO (1) | WO1996040966A1 (fr) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU754006B2 (en) * | 1998-03-17 | 2002-10-31 | Chugai Seiyaku Kabushiki Kaisha | Preventives or remedies for inflammatory intestinal diseases containing as the active ingredient IL-6 antagonists |
RU2392967C2 (ru) * | 2003-10-17 | 2010-06-27 | Тугаи Сейяку Кабусики Кайся | Терапевтический агент для мезотелиомы |
US8440196B1 (en) | 1998-08-24 | 2013-05-14 | Chugai Seiyaku Kabushiki Kaisha | Treatment for pancreatitis using IL-6 receptor antagonist antibodies |
RU2666942C1 (ru) * | 2017-08-14 | 2018-09-13 | федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр имени В.А. Алмазова" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ им. В.А. Алмазова" Минздрава России) | Способ лечения полинейромиопатии критических состояний у реанимационных больных |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0448181A2 (fr) * | 1990-03-23 | 1991-09-25 | Yamanouchi Europe B.V. | Compositions inhibitrices de l'interleukine-6 |
EP0696594A1 (fr) * | 1994-08-10 | 1996-02-14 | Bayer Corporation | Inhibiteur d'interleukine-6 humaine |
-
1996
- 1996-06-04 WO PCT/US1996/008679 patent/WO1996040966A1/fr active Application Filing
- 1996-06-04 AU AU60381/96A patent/AU6038196A/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0448181A2 (fr) * | 1990-03-23 | 1991-09-25 | Yamanouchi Europe B.V. | Compositions inhibitrices de l'interleukine-6 |
EP0696594A1 (fr) * | 1994-08-10 | 1996-02-14 | Bayer Corporation | Inhibiteur d'interleukine-6 humaine |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU754006B2 (en) * | 1998-03-17 | 2002-10-31 | Chugai Seiyaku Kabushiki Kaisha | Preventives or remedies for inflammatory intestinal diseases containing as the active ingredient IL-6 antagonists |
KR100407811B1 (ko) * | 1998-03-17 | 2003-12-01 | 츄가이 세이야꾸 가부시키가이샤 | 인터루킨-6 안타고니스트를 유효성분으로서 함유하는 염증성 장질환의 예방 또는 치료제 |
US6723319B1 (en) | 1998-03-17 | 2004-04-20 | Chugai Seiyaku Kabushiki Kaisha | Method of treating inflammatory intestinal diseases containing as the ingredient IL-6 receptors antibodies |
US7824674B2 (en) | 1998-03-17 | 2010-11-02 | Chugai Seiyaku Kabushiki Kaisha | Preventive or therapeutic agent for inflammatory bowel disease comprising IL-6 antagonist as an active ingredient |
US8440196B1 (en) | 1998-08-24 | 2013-05-14 | Chugai Seiyaku Kabushiki Kaisha | Treatment for pancreatitis using IL-6 receptor antagonist antibodies |
RU2392967C2 (ru) * | 2003-10-17 | 2010-06-27 | Тугаи Сейяку Кабусики Кайся | Терапевтический агент для мезотелиомы |
AU2004281139B2 (en) * | 2003-10-17 | 2011-01-20 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic agent for mesothelioma |
US8802092B2 (en) | 2003-10-17 | 2014-08-12 | Chugai Seiyaku Kabushiki Kaisha | Mesothelioma therapeutic agent |
RU2666942C1 (ru) * | 2017-08-14 | 2018-09-13 | федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр имени В.А. Алмазова" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ им. В.А. Алмазова" Минздрава России) | Способ лечения полинейромиопатии критических состояний у реанимационных больных |
Also Published As
Publication number | Publication date |
---|---|
AU6038196A (en) | 1996-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bellone et al. | Regulation of NK cell functions by TGF-beta 1. | |
Jubert et al. | Effects of surgery, anesthesia and intraoperative blood loss on immunocompetence | |
Hunter et al. | Production of gamma interferon by natural killer cells from Toxoplasma gondii-infected SCID mice: regulation by interleukin-10, interleukin-12, and tumor necrosis factor alpha | |
US4683199A (en) | Interleukin-2 dependent cytotoxic T-cell clones | |
PL181042B1 (pl) | Polipeptyd, przeciwciało i kompozycja farmaceutyczna | |
US20060275298A1 (en) | Antagonist of Th-1 immuneresponse inducing cytokine for the treatment of autoimmune diseases | |
Hawrylowicz et al. | Regulation of antigen-presentation-I. IFN-gamma induces antigen-presenting properties on B cells. | |
Patarca-Montero et al. | Immunology of chronic fatigue syndrome | |
Di Francesco et al. | In vivo cocaine administration influences lymphokine production and humoral immune response | |
VANOLI et al. | A case of Churg-Strauss vasculitis after hepatitis B vaccination | |
Kasama et al. | Biphasic regulation of the development of murine type II collagen–induced arthritis by interleukin‐12: possible involvement of endogenous interleukin‐10 and tumor necrosis factor α | |
Jayaraman et al. | Enhancement of in vivo cell-mediated immune responses by three distinct cytokines. | |
CN102245205A (zh) | 用于减少b-辅助性t细胞以治疗自身免疫疾病的方法 | |
CN1946734B (zh) | 系统性治疗关节炎的组合物和方法 | |
WO1996040966A1 (fr) | Compositions et procedes de traitement de maladies associees a l'interleukine 6 (il-6) | |
AU1051195A (en) | Compositions and method for stimulating antibody release by b lymphocytes | |
JPH03505211A (ja) | 好酸球増加症の予防または鎮静用薬剤 | |
JPH08245414A (ja) | Il−6関連疾患の治療用組成物および方法 | |
JP2823453B2 (ja) | インターロイキン−6の医薬組成物 | |
JPS6236325A (ja) | リユ−マチ性関節炎のような自已免疫疾患の抑制因子による治療 | |
PT97107A (pt) | Metodo para aumentar o crescimento e proliferacao de mastocitos utilizando interleuquina-9-purificada | |
JP3138481B2 (ja) | 自己免疫疾患および特にインスリン―依存性糖尿病の治療のためのil―7の使用 | |
Hollander | Immunotherapy of lymphoid and nonlymphoid tumors with monoclonal anti-Lyt-1 antibodies. | |
Plebanski et al. | Dependency on interleukin‐1 of primary human in vitro T cell responses to soluble antigens | |
Sun et al. | Human prolactin improves engraftment and reconstitution of human peripheral blood lymphocytes in SCID mice |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA MX |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |